These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1386 related articles for article (PubMed ID: 31492187)
21. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC. Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272 [TBL] [Abstract][Full Text] [Related]
22. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer. Orhan E; Velazquez C; Tabet I; Fenou L; Rodier G; Orsetti B; Jacot W; Sardet C; Theillet C Cancer Lett; 2024 May; 589():216820. PubMed ID: 38574883 [TBL] [Abstract][Full Text] [Related]
23. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition. Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743 [TBL] [Abstract][Full Text] [Related]
24. Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer. Meyer F; Becker S; Classen S; Parplys AC; Mansour WY; Riepen B; Timm S; Ruebe C; Jasin M; Wikman H; Petersen C; Rothkamm K; Borgmann K Cells; 2020 Jan; 9(1):. PubMed ID: 31963582 [TBL] [Abstract][Full Text] [Related]
25. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619 [TBL] [Abstract][Full Text] [Related]
26. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors. Do KT; Kochupurakkal B; Kelland S; de Jonge A; Hedglin J; Powers A; Quinn N; Gannon C; Vuong L; Parmar K; Lazaro JB; D'Andrea AD; Shapiro GI Clin Cancer Res; 2021 Sep; 27(17):4710-4716. PubMed ID: 34131002 [TBL] [Abstract][Full Text] [Related]
27. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. Li M; Li A; Zhou S; Lv H; Yang W J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840 [TBL] [Abstract][Full Text] [Related]
28. Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. Ha DH; Min A; Kim S; Jang H; Kim SH; Kim HJ; Ryu HS; Ku JL; Lee KH; Im SA Sci Rep; 2020 Jun; 10(1):9930. PubMed ID: 32555285 [TBL] [Abstract][Full Text] [Related]
29. MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells. Zeng X; Jiang S; Ruan S; Guo Z; Guo J; Liu M; Ye C; Dong J Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34080025 [TBL] [Abstract][Full Text] [Related]
30. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466 [TBL] [Abstract][Full Text] [Related]
31. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143 [TBL] [Abstract][Full Text] [Related]
39. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks. Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib. Zhao Q; Guan J; Zhang Z; Lv J; Wang Y; Liu L; Zhou Q; Mao W Biomed Pharmacother; 2017 Oct; 94():165-168. PubMed ID: 28759753 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]